Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The TBL1Y(A) USP9Y(A) haplotype of the Y chromosome, present only in black people of African origin, attributes a favorable lipoprotein pattern, likely to contribute to their reduced susceptibility to coronary heart disease.
|
18511697 |
2008 |
Male infertility
|
0.140 |
GeneticVariation
|
phenotype |
LHGDN |
Tracking microdeletions of the AZF region in a patrilineal line of infertile men.
|
18752188 |
2008 |
Azoospermia
|
0.140 |
Biomarker
|
disease |
BEFREE |
The association of this large deletion with normal fertility shows that USP9Y, hitherto considered a candidate gene for infertility and azoospermia, does not have a key role in male reproduction.
|
19246359 |
2009 |
Oligospermia
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Deletions in the azoospermia factor region AZFa on the human Y chromosome and, more specifically, in the region that encompasses the ubiquitin-specific peptidase 9, Y-linked gene USP9Y have been implicated in infertility associated with oligospermia and azoospermia.
|
19246359 |
2009 |
Partial chromosome Y deletion
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Genetic dissection of the AZF regions of the human Y chromosome: thriller or filler for male (in)fertility?
|
20671934 |
2010 |
Male sterility due to Y-chromosome deletions
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Genetic dissection of the AZF regions of the human Y chromosome: thriller or filler for male (in)fertility?
|
20671934 |
2010 |
Partial chromosome Y deletion
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Screening for partial AZFa microdeletions in the Y chromosome of infertile men: is it of clinical relevance?
|
22537385 |
2012 |
Male sterility due to Y-chromosome deletions
|
0.300 |
ChromosomalRearrangement
|
phenotype |
ORPHANET |
Screening for partial AZFa microdeletions in the Y chromosome of infertile men: is it of clinical relevance?
|
22537385 |
2012 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer.
|
25188740 |
2014 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level.
|
26008593 |
2015 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction was performed to evaluate the expression of TTTY15-USP9Y and the prostate cancer-specific antigen (PSA) level.
|
26008593 |
2015 |